Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
NESS ZIONA, Israel, Sept. 09, 2016 -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that its Chief Financial Officer, Gil Efron, and Vice President and Medical Director, Eran Schenker, will present a corporate overview at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference, taking place September 11-13 at the Lotte New York Palace Hotel in New York City.
Kamada Presentation Details
| Date: | Tuesday, September 13 | ||||
| Time: | 11:40am Eastern Time | ||||
| Location: | Lotte New York Palace Hotel | ||||
| Webcast: | http://wsw.com/webcast/rrshq26/kmda |
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia® in the U.S. through a strategic partnership with Baxalta (formerly Baxter International Inc.’s BioScience business and now part of Shire plc) and in other counties through local distributors. In addition to Glassia®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that its MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in Europe. Kamada has also completed its Phase 2 clinical trials in the U.S. In addition, Kamada's intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
CONTACTS: Gil Efron Chief Financial Officer [email protected] Bob Yedid LifeSci Advisors, LLC 646-597-6989 [email protected]
